HER2-low breast cancers: Current insights and future directions

• Published in: Seminars in diagnostic pathology Vol. 39; no. 5; pp. 305 - 312
• Main Authors: Zhang, Huina, Karakas, Cansu, Tyburski, Haley, Turner, Bradley M, Peng, Yan, Wang, Xi, Katerji, Hani, Schiffhauer, Linda, Hicks, David G
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2022
• Subjects: Biology; Breast cancer; HER2; HER2-low; Pathology; T-Dxd; Trastuzumab-deruxtecan; Pathology; HER2-low; T-Dxd; Trastuzumab-deruxtecan; Breast cancer; Biology; HER2

In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials, particularly trastuzumab-deruxtecan (T-Dxd), the new “HER2-low” category in breast cancers (breast cancer with a H...